Palvella Therapeutics exceeded enrollment target for Phase 3 SELVA trial and has positive financial outlook.

From GlobeNewswire: 2025-05-15 07:30:00

Palvella Therapeutics has exceeded enrollment target for Phase 3 SELVA trial of QTORIN™ rapamycin for lymphatic malformations. Phase 2 TOIVA trial results expected in Q4 2025. Cash reserves of $75.6 million to fund operations through 2027. Conference call scheduled for today at 8:30 a.m. ET. Top-line results anticipated in Q1 2026.

QTORIN™ rapamycin shows promise for treating microcystic LMs and cutaneous venous malformations. Recent Phase 2 study results published in JoVA. Patent granted for microcystic LMs treatment. First patients dosed in TOIVA Phase 2 trial for cutaneous VMs. Cash and equivalents as of March 31, 2025, were $75.6 million.

Palvella Therapeutics reported a net loss of $8.2 million for the first quarter of 2025. Research and development expenses increased due to clinical trials for QTORIN™ rapamycin. General and administrative expenses also rose. Shares outstanding were 13,697,114 as of March 31, 2025.

Investors and media can contact Palvella Therapeutics for more information. Financial statements show a net loss of $8.2 million for the first quarter of 2025. Cash and cash equivalents as of March 31, 2025, were $75.6 million. Total assets and liabilities reported for the same period.



Read more at GlobeNewswire:: Palvella Therapeutics Reports First Quarter 2025 Financial